Steris Shares 14.8% Decline Over Three Months, Analysts Project 34% Upside
STERIS’s shares have slid 14.8% over the past three months and are 20.4% below their 52-week high of $269.44, trading under both 50-day and 200-day moving averages. Steris reported Q3 revenue of $1.50B and EPS of $2.53; analysts hold a Moderate Buy rating with a $288.43 target implying 34.4% upside.
1. Technical Underperformance
Over the past three months, Steris shares declined 14.8% versus a 4.7% drop in the Nasdaq Composite, and sit 20.4% below their 52-week high of $269.44. The stock has traded below its 50-day moving average since early February and fallen beneath its 200-day moving average since early March, signaling sustained selling pressure.
2. Q3 Financial Results
In its third quarter, Steris generated $1.50 billion in revenue, beating analyst forecasts of $1.48 billion, and reported EPS of $2.53, in line with estimates. The mixed performance highlights steady demand for its infection prevention products despite broader market headwinds.
3. Analyst Outlook
Nine analysts maintain a Moderate Buy rating on Steris, with a consensus price target of $288.43, representing a potential 34.4% upside. Investor optimism centers on Steris’s leading market position in sterilization and equipment management solutions and its resilient revenue streams.